News

The collaboration combines Bend Research’s advanced drug formulation capabilities and Quotient Clinical’s clinical-trial design service, RapidFACT (Rapid Formulation development And Clinical Testing). RapidFACT represents a new paradigm for

ProPhase Labs has posted a net loss of $947,000 for the third quarter 2010, or $0.06 loss per diluted share, compared to net loss of $1.2m, or $0.09

SuperGen said that the dose limiting toxicity of cardiac QTc prolongation was identified previously in the Phase 1 study in patients with refractory prostate and lymphoma. Additional detailed

Nuvo is primarily focused on the R&D of drug products delivered into and through the skin using its topical and transdermal drug delivery technologies, and on the development

The IntegenX programs focus on developing platforms for DNA sample preparation, sequencing library preparation and sample-to-answer analysis of human genotypes. IntegenX president and CEO Stevan Jovanovich said that

In January this year Novartis had agreed to invest $24m to secure access to chip-in-a-pill technology developed by California-based privately held firm Proteus Biomedical, Reuters reported. The embedded

The winds of change seem fairly constant in the pharmaceutical industry. Complex legislative and regulatory issues, increased competition, complex company structures, and mergers and acquisitions all impact on

As a result of current agreement, MicroDose’s inhaler is able to wirelessly upload dosing and compliance information from the inhaler to a web-based server for data management and

BMP Sunstone has posted a net loss of $1.26m for the third quarter 2010, or $0.03 loss per diluted share, compared to net loss of $208,000 or $0.01